Highlights PepGen Inc.

Equities

PEPG

US7133171055

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
14.2 ^USD	-2.00%		+19.03%	+108.82%

Mar. 13	PepGen Says Potential Duchenne Muscular Dystrophy Treatment Gets FDA Orphan Drug, Rare Pediatric Disease Designations	MT
Mar. 13	PepGen's Rare Muscle Disorder Therapy Gets FDA Orphan Drug, Rare Pediatric Disease Designations	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PepGen Says Potential Duchenne Muscular Dystrophy Treatment Gets FDA Orphan Drug, Rare Pediatric Disease Designations	Mar. 13	MT
PepGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
PepGen Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 06	CI
PepGen Inc. Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	Mar. 04	CI
PepGen Says FDA Grants Fast Track Designation to Potential Myotonic Dystrophy Type 1 Treatment	Feb. 20	MT
PepGen Inc. Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1	Feb. 20	CI
Pepgen Inc. Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of P GN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping	Jan. 08	CI
Pepgen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1	Dec. 18	CI
PepGen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
PepGen Says FDA Lifted Clinical Hold on Application to Begin Myotonic Dystrophy Type 1 Phase 1 Study	23-10-12	MT
PepGen Inc. Announces FDA Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1	23-10-12	CI
PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company's Enhanced Delivery Oligonucleotide Platform and PGN-EDO Program at Two Medical Conferences	23-09-06	CI
PepGen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
PepGen Withdraws Timeline on Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1	23-06-13	MT
PepGen Withdraws Guidance on Launch of Study for Muscle Disease Treatment	23-06-13	DJ
PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1	23-06-13	CI
PepGen Gets Clinical Hold Notice From FDA for Application to Launch DM1 Trial; Shares Plunge After-Hours	23-05-30	MT
Pepgen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate A Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1	23-05-30	CI
PepGen Says Health Canada Cleared Phase 2 Study of Duchenne Muscular Dystrophy Treatment	23-05-18	MT
PepGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights PepGen Inc.

Equities

PEPG

US7133171055

Highlights

Filters